Related Experiment Video
Updated: Apr 28, 2026

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
Extracorporeal Membrane Oxygenation in Pediatric Severe Aplastic Anemia: A Case Report Highlighting Risk-Benefit and
Abigail S Abraham1, Merin M Mathew2, Lyndsey Thomas1
1College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, USA.
Insights
Extracorporeal membrane oxygenation (ECMO) use in pediatric severe aplastic anemia (SAA) carries significant risks. This case illustrates ECMO
Area of Science:
- Pediatric Hematology
- Critical Care Medicine
- Bone Marrow Failure Syndromes
Background:
- Severe aplastic anemia (SAA) is a rare pediatric disorder causing pancytopenia and high risks of infection and bleeding.
- Children with SAA are vulnerable to sepsis, and the role of extracorporeal membrane oxygenation (ECMO) is unclear due to bleeding and thrombotic risks.
Abstract:
Severe aplastic anemia (SAA) is a rare pediatric bone marrow failure disorder marked by profound pancytopenia and high risk of infection, bleeding, and organ dysfunction. Despite advances in definitive therapy, children with SAA remain vulnerable to rapid deterioration during neutropenic sepsis. The role of extracorporeal membrane oxygenation (ECMO) in this population is poorly defined due to substantial hemorrhagic, thrombotic, and infection risks, thus necessitating careful risk-benefit assessment. A four-year-old child presented with febrile neutropenia and profound pancytopenia and was diagnosed with idiopathic severe aplastic anemia based on bone marrow biopsy demonstrating marked hypocellularity. Her course was complicated by persistent marrow failure and recurrent infections despite supportive care. Four months later, she developed refractory septic shock requiring ECMO, which was complicated by severe bleeding, disseminated intravascular coagulation, venous thrombosis, and progressive multi-organ failure, resulting in death. This case highlights the narrow therapeutic window of ECMO in pediatric SAA, in which profound cytopenias and immunosuppression markedly increase morbidity. While ECMO may provide temporary cardiopulmonary stabilization, its benefit depends on the likelihood of hematologic recovery and a clear pathway to definitive therapy. The use of ECMO in pediatric severe aplastic anemia, therefore, requires cautious patient selection, early multidisciplinary collaboration, and proactive goals-of-care discussions to ensure alignment with prognosis and family-centered values.
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

